It was reported yesterday that Samsung Bioepis Co Ltd, a biopharmaceutical company, has signed a new commercialisation agreement with United States-based Biogen (Nasdaq: BIIB).
The contract has been signed for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States, Canada, Europe, Japan, and Australia.
SB11 is a biosimilar candidate referencing LUCENTIS (ranibizumab) and is currently undergoing a phase three clinical trial, while SB15 is a biosimilar candidate referencing EYLEAiii (aflibercept) and is in pre-clinical development.
The contract also offers Biogen an option to extend the commercialisation term for Samsung Bioepis' three anti-TNF biosimilars, BENEPALI (etanercept), FLIXABI (infliximab), and IMRALDI (adalimumab) in Europe for an additional five years beyond its original ten-year contract. It also offers Biogen an option to receive commercialisation rights to BENEPALI, FLIXABI and IMRALDI in China in exchange for royalties on sales in the market.
GlaxoSmithKline's Nucala succeeds in phase three hypereosinophilic syndrome study
Calliditas Therapeutics appoints new CMO
Promethera Biosciences, Medipal Enter Alliance Pact
Merck's ERVEBO Ebola Zaire Vaccine Granted Conditional Approval in the European Union
NEC and Vaximm Forge Clinical Trial Collaboration
US FDA grants Breakthrough Therapy Designation to X4 Pharmaceuticals' mavorixafor